Jupiter Neurosciences Finalizes 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance
JUNS is trading near its 52-week low of $0.071 (9.4% above the low).
Summary
Jupiter Neurosciences implemented a 1-for-75 reverse stock split to regain Nasdaq's $1 minimum bid compliance, reducing outstanding shares to ~770,000. The move addresses an immediate delisting threat but does not resolve the company's going concern warning or cash needs.
Key Events · Corporate Governance and Compliance · JUNS
-
1-for-75 Reverse Stock Split Executed
Effective August 6, 2026, every 75 shares of common stock are combined into one, reducing outstanding shares from ~57.76 million to ~770,000. Post-split trading begins August 7 under the same ticker JUNS.
-
Nasdaq Compliance Bid
The reverse split aims to raise the stock price above Nasdaq's $1.00 minimum bid requirement. At the pre-split price of $0.0777, the post-split price would be approximately $5.83, providing a buffer against delisting.
-
No Change to Authorized Shares
The total authorized shares remain unchanged, meaning the company retains significant headroom for future dilution. Proportional adjustments are made to outstanding options, warrants, and convertible securities.
-
Financial Distress Context
The company has a going concern warning, a $4.4M market cap, and recently completed a $2.0M direct offering at $0.28/share. The reverse split is a survival measure, not a fundamental improvement.
Analysis · JUNS · Life Sciences
Jupiter Neurosciences is executing a 1-for-75 reverse stock split effective today, reducing outstanding shares from approximately 57.8 million to about 770,000. This is a last-ditch effort to boost the stock price above Nasdaq's $1 minimum bid requirement and avoid delisting. The company has been under severe financial distress with a going concern warning, dilutive financing, and a stock price of just $0.0777 pre-split. While the reverse split mechanically raises the per-share price, it does not change the company's market cap or underlying fundamentals. The move buys time but comes with significant risks: post-split stocks often decline as the overhang of authorized but unissued shares remains, and the company's cash runway is critically short. The split was approved by shareholders on July 22, 2026, and the specific 1-for-75 ratio was set by the board within the authorized range.
At the time of this filing, JUNS was trading at $0.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $0.07 to $1.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.